TDOC heads into Q4 earnings with an improving loss outlook and rising Integrated Care EBITDA, but BetterHelp declines may weigh on revenues.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

GoodRx (NASDAQ: GDRX - Get Free Report) and Teladoc Health (NYSE: TDOC - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings. Earnings and Valuation This table compares GoodRx and

Teladoc (TDOC) reached $4.56 at the closing of the latest trading day, reflecting a -1.94% change compared to its last close.

Teladoc has seen its share price tumble 98% from its 2021 peak. It has declining revenue and is not profitable.

Teladoc (TDOC) closed at $4.85 in the latest trading session, marking a -2.61% move from the prior day.

Shares of Teladoc Health, Inc. (NYSE: TDOC - Get Free Report) have been given an average rating of "Hold" by the sixteen brokerages that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation and three have issued a buy recommendation on

NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE: TDOC), the global leader in virtual care, announced that it will release fourth quarter 2025 results on Wednesday, February 25, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day.

Teladoc stock price crashed to a record low as demand for its services waned after the pandemic. It plunged to a low of $5.74, down sharply from the all-time high of $308, with its market capitalization falling from a high of $46 billion to the current $1 billion.

Teladoc stock has dropped more than 70% in recent years.